Status:
COMPLETED
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
Lead Sponsor:
Watson Pharmaceuticals
Conditions:
Anemia, Iron-Deficiency
Kidney Failure, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study explores the safety and efficacy of intravenous iron therapy in anemic hemodialysis patients treated with epoetin alfa, who have higher serum ferritin levels, but low to normal transferrin ...
Eligibility Criteria
Inclusion
- Chronic hemodialysis
- Elevated serum ferritin with low to normal transferrin saturation (TSAT)
- Moderate to severe anemia
- Receiving epoetin alfa treatment
Exclusion
- Known sensitivity to Ferrlecit®
- Medical conditions that would confound the efficacy evaluation
- Recent blood transfusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT00224081
Start Date
September 1 2004
Last Update
December 10 2015
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Bakersfield, California, United States
2
Glendale, California, United States
3
Los Angeles, California, United States
4
Santa Rosa, California, United States